Damora Therapeutics fell 1.6% from $22.85 to $22.50, behind the S&P 500's +11.2%. Its worst day was Dec 30 (−24.7%), and its low came Nov 24 at $16.31.
Story events cover the past 12 months · Times ET
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Damora Therapeutics closed at its lowest level of the year, 28.6% below where the year started.
−2.7% · S&P 500 +1.5%
Damora Therapeutics shares rose 24.5%, while the S&P 500 rose 0.1%.
+24.5% · S&P 500 +0.1%
Damora Therapeutics closed at its highest level of the year, 49.4% above where the year started.
+15.8% · S&P 500 0.0%
Damora Therapeutics shares rose 37.8%, while the S&P 500 fell 1.5%.
+37.8%, the year's best day · S&P 500 −1.5%
EPS of $2.90 beat the $-0.12 estimate on $0.00 revenue.
−5.5% · S&P 500 −1.4%
EPS of $-0.62 missed the $-0.56 estimate on $0.00 revenue.
+4.6% · S&P 500 +0.6%
EPS of $-0.39 missed the $-0.37 estimate on $0.00 revenue.
+2.8% · S&P 500 −0.3%
EPS of $-0.40 beat the $-0.45 estimate on $0.00 revenue.
−4.7% · S&P 500 −4.4%
Where it ended: a close of $22.50 on Nov 16, 2026.
Nothing in the past 12 months.
All DMRA dividend history